Playing catch-up, Boehringer taps RetinAI for AI boost to eye disease R&D

Boehringer Ingelheim has tapped RetinAI to support its attempt to develop treatments for geographic atrophy (GA), striking a deal to apply artificial intelligence tools to its imaging data in a search for novel biomarkers and predictors of disease progression.